BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 21106881)

  • 1. HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy.
    Fukuoka H; Cooper O; Mizutani J; Tong Y; Ren SG; Bannykh S; Melmed S
    Mol Endocrinol; 2011 Jan; 25(1):92-103. PubMed ID: 21106881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas.
    Cooper O; Bonert VS; Rudnick J; Pressman BD; Lo J; Salvatori R; Yuen KCJ; Fleseriu M; Melmed S
    J Clin Endocrinol Metab; 2021 Jan; 106(2):e917-e925. PubMed ID: 33150390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands.
    Vlotides G; Siegel E; Donangelo I; Gutman S; Ren SG; Melmed S
    Cancer Res; 2008 Aug; 68(15):6377-86. PubMed ID: 18676863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic mice.
    Liu X; Kano M; Araki T; Cooper O; Fukuoka H; Tone Y; Tone M; Melmed S
    Endocrinology; 2015 Jan; 156(1):71-9. PubMed ID: 25375038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors.
    Cooper O; Mamelak A; Bannykh S; Carmichael J; Bonert V; Lim S; Cook-Wiens G; Ben-Shlomo A
    Endocrine; 2014 Jun; 46(2):318-27. PubMed ID: 24287797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heregulin regulates prolactinoma gene expression.
    Vlotides G; Cooper O; Chen YH; Ren SG; Greenman Y; Melmed S
    Cancer Res; 2009 May; 69(10):4209-16. PubMed ID: 19401448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.
    Zhang Z; Oyesanya RA; Campbell DJ; Almenara JA; Dewitt JL; Sirica AE
    Hepatology; 2010 Sep; 52(3):975-86. PubMed ID: 20607690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endogenous expression of Neuregulin-1 (Nrg1) as a potential modulator of prolactin (PRL) secretion in GH3 cells.
    Zhao W; Shen Y; Ren S
    Cell Tissue Res; 2011 May; 344(2):313-20. PubMed ID: 21437657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibiting MAPK14 showed anti-prolactinoma effect.
    Ding QY; Zhang Y; Ma L; Chen YG; Wu JH; Zhang HF; Wang X
    BMC Endocr Disord; 2020 Sep; 20(1):138. PubMed ID: 32894113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells.
    Ben-Shlomo A; Miklovsky I; Ren SG; Yong WH; Heaney AP; Culler MD; Melmed S
    J Clin Endocrinol Metab; 2003 Feb; 88(2):858-63. PubMed ID: 12574225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.
    Karakashev SV; Reginato MJ
    Oncotarget; 2015 Feb; 6(4):1967-80. PubMed ID: 25596742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
    Gilmer TM; Cable L; Alligood K; Rusnak D; Spehar G; Gallagher KT; Woldu E; Carter HL; Truesdale AT; Shewchuk L; Wood ER
    Cancer Res; 2008 Jan; 68(2):571-9. PubMed ID: 18199554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dual targeting of EGFR and ErbB2 with the inhibitor Lapatinib corrects high glucose-induced apoptosis and vascular dysfunction by opposing multiple diabetes-induced signaling changes.
    Benter IF; Sarkhou F; Al-Khaldi AT; Chandrasekhar B; Attur S; Dhaunsi GS; Yousif MH; Akhtar S
    J Drug Target; 2015; 23(6):506-18. PubMed ID: 26114862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2.
    Kim HP; Yoon YK; Kim JW; Han SW; Hur HS; Park J; Lee JH; Oh DY; Im SA; Bang YJ; Kim TY
    PLoS One; 2009 Jun; 4(6):e5933. PubMed ID: 19529774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor cross-talks with ligand-occupied estrogen receptor-alpha to modulate both lactotroph proliferation and prolactin gene expression.
    Chen S; Bangaru ML; Sneade L; Dunckley JA; Ben-Jonathan N; Kansra S
    Am J Physiol Endocrinol Metab; 2009 Aug; 297(2):E331-9. PubMed ID: 19470835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines.
    Rusnak DW; Alligood KJ; Mullin RJ; Spehar GM; Arenas-Elliott C; Martin AM; Degenhardt Y; Rudolph SK; Haws TF; Hudson-Curtis BL; Gilmer TM
    Cell Prolif; 2007 Aug; 40(4):580-94. PubMed ID: 17635524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma.
    Guo XF; Zhu XF; Zhong GS; Deng BG
    Dis Esophagus; 2013 Jul; 26(5):487-95. PubMed ID: 22458639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor.
    Juliachs M; Castillo-Ávila W; Vidal A; Piulats JM; Garcia Del Muro X; Condom E; Hernández-Losa J; Teixidó C; Pandiella A; Graupera M; Casanovas O; Germà JR; Villanueva A; Viñals F
    Int J Cancer; 2013 Jul; 133(1):235-46. PubMed ID: 23292912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen receptor-alpha mediates the epidermal growth factor-stimulated prolactin expression and release in lactotrophs.
    Ben-Jonathan N; Chen S; Dunckley JA; LaPensee C; Kansra S
    Endocrinology; 2009 Feb; 150(2):795-802. PubMed ID: 18832099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
    Hickinson DM; Klinowska T; Speake G; Vincent J; Trigwell C; Anderton J; Beck S; Marshall G; Davenport S; Callis R; Mills E; Grosios K; Smith P; Barlaam B; Wilkinson RW; Ogilvie D
    Clin Cancer Res; 2010 Feb; 16(4):1159-69. PubMed ID: 20145185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.